Core Points - A product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" claimed a phospholipid content of 43%, but actual tests showed it to be 0, indicating potential false advertising and consumer rights violations [2] - The distributor of the product is Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., while the manufacturer is Anhui Hab Pharmaceutical Co., Ltd. Beijing Tongrentang Health Pharmaceutical Co., Ltd. stated that the product was unauthorized and will pursue legal action against the involved companies [2] - The relationship between the companies is complex, with Beijing Tongrentang Health Pharmaceutical Co., Ltd. holding a 51% stake in Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., raising questions about accountability and the potential damage to the Tongrentang brand [2] Company and Industry Summary - The incident highlights issues of brand integrity and consumer trust within the health product industry, particularly for established brands like Beijing Tongrentang [2] - The Shanghai Consumer Protection Committee's involvement indicates regulatory scrutiny and the potential for broader implications for the industry regarding product labeling and consumer rights [2] - The situation raises concerns about the responsibilities of parent companies in overseeing the actions of their subsidiaries, especially in the context of product quality and marketing claims [2]

Core Viewpoint - A product claiming to be "99% pure Antarctic krill oil" from "Beijing Tongrentang" was found to contain "0" krill oil, raising concerns about misleading marketing practices and consumer protection [1][3][12]. Group 1: Product Misrepresentation - The Shanghai Consumer Protection Commission tested 15 popular Antarctic krill oil products and discovered that the product in question had no actual krill oil content, despite claims of 43% phospholipid content [1][3]. - The manufacturer, Anhui Habao Pharmaceutical Co., admitted that the product was customized by the distributor, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., and did not contain the claimed krill oil [4][8]. - The product was sold at a price of 60 yuan per bottle, while the manufacturer's cost was only 3 to 3.7 yuan, raising questions about the legitimacy of the pricing and the quality of the ingredients [4][11]. Group 2: Misleading Branding - The packaging prominently featured "Beijing Tongrentang," which misled consumers into believing it was a product directly from the well-known brand, while it was actually from a different company [4][7]. - The product's branding utilized a design that closely resembled the core trademark of Beijing Tongrentang, creating a deceptive impression of authenticity [7][19]. - The distributor claimed that misleading packaging decisions were made by the manufacturer, while the manufacturer stated that the packaging was designed according to the distributor's specifications, indicating a shared responsibility for the misleading marketing [8][11]. Group 3: Broader Industry Implications - The incident is not isolated; there is a larger trend of "borderline" products using the Tongrentang name to mislead consumers, with similar products also found on e-commerce platforms [12][18]. - The Shanghai Consumer Protection Commission urged the distributor to conduct a self-examination, apologize to consumers, and recall the problematic products [19][20]. - Beijing Tongrentang Health Pharmaceutical Co. announced that it would stop the distribution of the implicated product and initiate legal action against the responsible parties for unauthorized use of its name [19][20].

Core Viewpoint - The Shanghai Consumer Rights Protection Committee has accused Anhui Habio Pharmaceutical Co., Ltd. and Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. of potential fraud regarding the "99% High Purity Antarctic Krill Oil" product, highlighting serious discrepancies between product claims and actual content [1] Group 1: Company Actions - Anhui Habio Pharmaceutical admitted that the product did not contain the claimed "Antarctic krill oil" during production [1] - Beijing Tongrentang (Sichuan) Health claimed ignorance of the alleged fraudulent behavior and distanced itself from responsibility during the inquiry [1] Group 2: Investigation Findings - The Shanghai Consumer Rights Protection Committee found evidence of intentional fraud, noting that the product falsely claimed a phospholipid content of 43% while lacking the advertised ingredient [1] - The investigation revealed deliberate misleading practices in product packaging and marketing [1] Group 3: Recommendations - The Shanghai Consumer Rights Protection Committee has recommended that Beijing Tongrentang (Sichuan) Health conduct a self-examination, issue an apology for the infringement, recall the problematic products, and provide legal compensation [1]

Group 1 - The Shanghai Consumer Protection Commission has disclosed that it has interviewed distributors and manufacturers regarding issues related to Antarctic krill oil products [1] - Anhui Hab Pharmaceutical Co., Ltd. admitted that the products in question did not contain the claimed "Antarctic krill oil" during the production process [1] - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. evaded responsibility during the interview, claiming ignorance of the alleged fraudulent behavior [1] Group 2 - The Shanghai Consumer Protection Commission has urged Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. to conduct a self-examination and inform consumers of the situation [2] - The commission has requested that the company sincerely apologize to consumers for infringing on their rights [2] - The commission has also called for a recall of the problematic products and for the companies involved to process refunds and compensations for consumers [2]

Core Viewpoint - A product labeled as "99% high-purity Antarctic krill oil" produced by Anhui Habio Pharmaceutical Co., Ltd. and distributed by Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. is reported to have false ingredient labeling, prompting legal action by the company to protect consumer rights and brand integrity [1] Group 1 - The company has ordered Sichuan Health Pharmaceutical to cease distribution of the implicated product and is conducting a full process investigation and traceability [1] - The product was unauthorizedly labeled with "Beijing Tongrentang," which is considered illegal, leading the company to initiate legal proceedings against the involved enterprises [1] - The company emphasizes its commitment to product quality and consumer health, pledging to strengthen management and resist actions that could harm consumer health and brand image [1] Group 2 - The company urges consumers to purchase products through official channels and to recognize the "Tongrentang" double-dragon logo to avoid potential rights violations [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | | 1 RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | | 1 RMB | | 652,080,000 | | 2. 股份分類 ...

Core Viewpoint - Tong Ren Tang Technologies (01666.HK) announced changes in its company secretary and board secretary positions effective November 28, 2025, due to personal reasons and work adjustments of the current holders [1] Group 1: Management Changes - Li Yijun has resigned as the company secretary, board secretary, and authorized representative under the Hong Kong Stock Exchange Listing Rule 3.05 due to family reasons [1] - Weng Meiyi will no longer serve as the agent for receiving legal documents and notifications in Hong Kong due to work adjustments [1] - Ma Yongyi has been appointed as the new company secretary, authorized representative, and legal document agent effective November 28, 2025 [1] - Han Guanzhao has been appointed as the new board secretary effective November 28, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立的股份有限公司 ) 由於商標許可補充協議項下的持續關連交易之經修訂年度上限之一項或多項使 用百分比率（定義見香港上市規則）高於0.1%但低於5%，故該持續關連交易須 遵守香港上市規則第14A章項下之公告、申報及年度審閱規定，惟獲豁免遵守 通函及獨立股東批准規定。 (股份代號：1666) 修訂年度上限及持續關連交易條款的變動 商標許可補充協議 商標許可補充協議 茲提述本公司日期為二零二四年十二月三十日及二零二五年一月九日之公告， 其中內容有關本公司與集團公司訂立現有商標許可協議，以允許本集團有償使 用「同仁堂」字號及部分商標（同仁堂國藥及其附屬公司/參股公司以及國藥集 團及其附屬公司/參股公司豁免收費），協議期限自二零二五年一月一日起至二 零二七年十二月三十一日止。 於二零二五年十一月二十八日，同仁堂國藥宣佈與集團公司訂立了新商標許可 框架協議以允許同仁堂國藥於二零二六年一月一 ...

Core Viewpoint - Tongrentang Technology (01666) announced changes in its company secretary and board secretary positions effective November 28, 2025 [1] Group 1: Management Changes - Mr. Li Yijun has resigned from the positions of company secretary, board secretary, and authorized representative under the Hong Kong Stock Exchange Listing Rules due to family reasons [1] - Ms. Weng Meiyi will no longer serve as the agent for receiving legal documents and notifications in Hong Kong due to work adjustments [1] - Ms. Ma Yongyi has been appointed as the new company secretary, authorized representative, and legal process agent [1] - Mr. Han Guanzhao has been appointed as the new board secretary [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 關連交易 續訂現有土地使用權租賃協議 兹提述本公司二零二一年三月二十六日之公告，其內容有關本公司與集團公司於二零二一 年三月二十六日簽訂現有土地使用權租賃協議，據此，集團公司同意將土地租賃給本公司， 租賃期限自二零二零年十月六日起至二零二五年十月五日止，為期五年。鑒於現有土地使 用權租賃協議已到期，本公司與集團公司於二零二五年十一月二十八日簽訂續訂之土地使 用權租賃協議，租賃期限自二零二五年十月六日起至二零二八年十月五日止，為期三年。 截至本公告日，集團公司乃本公司之最終控股股東，故根據香港上市規則為本公司之關連 人士。根據國際財務報告準則第 16 號，本公司就續訂之土地使用權租賃協議項下的土地租 賃在其合併財務報表中確認使用權資產價值。因此，其項下擬進行的交易被視為本公司收 購使用權資產，將構成香港上市規則第 14A 章項下本公司的一次性關連交易。 由于本公司根据國際財務報告準則第 16 號項下的租賃資產就續訂之土地使用權租賃協議 確認之使用權資產價值之一项或多项適用百分比率（定義見香港上市規則第 14.07 條）高 於 0.1%但均低於 ...